May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?
作者信息
Scicali Roberto, Di Pino Antonino, Piro Salvatore, Rabuazzo Agata M, Purrello Francesco
机构信息
Department of Clinical and Experimental Medicine, University of Catania, Italy.
Department of Clinical and Experimental Medicine, University of Catania, Italy.
出版信息
Nutr Metab Cardiovasc Dis. 2020 Jun 25;30(7):1068-1069. doi: 10.1016/j.numecd.2020.05.003. Epub 2020 May 13.
Abstract
摘要
相似文献
1
May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?他汀类药物和前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂对家族性高胆固醇血症患者是否具有预防新型冠状病毒肺炎（COVID-19）的作用？
Nutr Metab Cardiovasc Dis. 2020 Jun 25;30(7):1068-1069. doi: 10.1016/j.numecd.2020.05.003. Epub 2020 May 13.
2
Older Familial Hypercholesterolemia Patients with COVID-19.老年家族性高胆固醇血症合并新型冠状病毒肺炎患者
Gerontology. 2021;67(5):608-610. doi: 10.1159/000514447. Epub 2021 Mar 18.
3
Editor's presentation: 'Les liaisones dangerouses. The heart in the time of COVID-19'.编辑介绍：《危险关系。新冠疫情下的心脏》
Eur J Prev Cardiol. 2020 Jul;27(10):1011-1013. doi: 10.1177/2047487320936413.
4
Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia.预防家族性高胆固醇血症的新冠肺炎患者出现内皮功能障碍和血栓形成事件。
J Clin Lipidol. 2020 Sep-Oct;14(5):617-618. doi: 10.1016/j.jacl.2020.06.006. Epub 2020 Jun 15.
5
Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis.结缔组织病患者中新型冠状病毒肺炎的发病率及临床病程：一项描述性观察分析
J Rheumatol. 2020 Aug 1;47(8):1296. doi: 10.3899/jrheum.200507. Epub 2020 Apr 25.
6
Familial hypercholesterolemia: Detect, treat, and ask about family.家族性高胆固醇血症：检测、治疗和询问家族史。
Cleve Clin J Med. 2020 Feb;87(2):109-120. doi: 10.3949/ccjm.87a.19021.
7
Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.载脂蛋白(a)表型决定了潜在家族性高胆固醇血症患者脂蛋白(a)和前蛋白转化酶枯草溶菌素/克那霉 9 水平的相关性。
Atherosclerosis. 2018 Oct;277:477-482. doi: 10.1016/j.atherosclerosis.2018.08.011.
8
Responding to COVID-19 in Hong Kong.香港应对新冠疫情。
Hong Kong Med J. 2020 Jun;26(3):164-166. doi: 10.12809/hkmj205101. Epub 2020 Jun 11.
9
Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle.乌兹别克斯坦家族性杂合子高胆固醇血症的负担：时间就是肌肉。
Atherosclerosis. 2018 Oct;277:524-529. doi: 10.1016/j.atherosclerosis.2018.08.016.
10
Genetic screening for familial hypercholesterolemia identifies patients not meeting cholesterol treatment guidelines.
Coron Artery Dis. 2021 Sep 1;32(6):588-589. doi: 10.1097/MCA.0000000000000998.
引用本文的文献
1
The Influence of SARS-CoV-2 Infection on Lipid Metabolism-The Potential Use of Lipid-Lowering Agents in COVID-19 Management.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染对脂质代谢的影响——降脂药物在2019冠状病毒病（COVID-19）治疗中的潜在应用
Biomedicines. 2022 Sep 18;10(9):2320. doi: 10.3390/biomedicines10092320.
2
Impact of Metabolic Risk Factors on COVID-19 Clinical Outcomes: An Extensive Review.代谢危险因素对 COVID-19 临床结局的影响：一篇全面的综述。
Curr Cardiol Rev. 2022;18(6):e090522204452. doi: 10.2174/1573403X18666220509154236.
3
Monocyte and Macrophage Lipid Accumulation Results in Down-Regulated Type-I Interferon Responses.单核细胞和巨噬细胞脂质蓄积导致I型干扰素反应下调。
Front Cardiovasc Med. 2022 Feb 10;9:829877. doi: 10.3389/fcvm.2022.829877. eCollection 2022.
4
Antiviral strategies targeting host factors and mechanisms obliging +ssRNA viral pathogens.针对宿主因子和机制的抗病毒策略，这些宿主因子和机制有利于 +ssRNA 病毒病原体。
Bioorg Med Chem. 2021 Sep 15;46:116356. doi: 10.1016/j.bmc.2021.116356. Epub 2021 Aug 8.
5
The protective association between statins use and adverse outcomes among COVID-19 patients: A systematic review and meta-analysis.他汀类药物使用与 COVID-19 患者不良结局之间的保护关联：系统评价和荟萃分析。
PLoS One. 2021 Jun 24;16(6):e0253576. doi: 10.1371/journal.pone.0253576. eCollection 2021.
6
Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets.新型冠状病毒肺炎中的脂质稳态和甲羟戊酸途径：基本概念和潜在治疗靶点。
Prog Lipid Res. 2021 Apr;82:101099. doi: 10.1016/j.plipres.2021.101099. Epub 2021 Apr 26.
7
Statin use is associated with lower disease severity in COVID-19 infection.他汀类药物的使用与 COVID-19 感染中的疾病严重程度降低有关。
Sci Rep. 2020 Oct 15;10(1):17458. doi: 10.1038/s41598-020-74492-0.
8
Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review.新型冠状病毒肺炎期间的心血管受累情况及对老年患者的临床意义。综述
Ann Med Surg (Lond). 2020 Aug 5;57:236-243. doi: 10.1016/j.amsu.2020.07.054. eCollection 2020 Sep.
9
[Lipid treatment in the period COVID-19].新冠疫情期间的脂质治疗
Semergen. 2020 Oct;46(7):497-502. doi: 10.1016/j.semerg.2020.06.014. Epub 2020 Jul 1.
本文引用的文献
1
Familial hypercholesterolaemia and COVID-19: triggering of increased sustained cardiovascular risk.家族性高胆固醇血症与2019冠状病毒病：引发持续升高的心血管风险
J Intern Med. 2020 Jun;287(6):746-747. doi: 10.1111/joim.13070. Epub 2020 Apr 22.
2
Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two-Lipid Center Real-World Experience.家族性高胆固醇血症患者在高强度他汀类药物基础上加用 PCSK9 抑制剂或依折麦布对动脉僵硬度的改善作用：双脂质中心真实世界经验。
J Clin Lipidol. 2020 Mar-Apr;14(2):231-240. doi: 10.1016/j.jacl.2020.01.015. Epub 2020 Feb 4.
3
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
4
Rewiring cellular networks by members of the Flaviviridae family.黄病毒科成员对细胞网络的重排。
Nat Rev Microbiol. 2018 Feb 12;16(3):125-142. doi: 10.1038/nrmicro.2017.170.
5
Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection.恢复期 SARS 患者感染 12 年后的脂质代谢改变。
Sci Rep. 2017 Aug 22;7(1):9110. doi: 10.1038/s41598-017-09536-z.
6
Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin.在高胆固醇血症中，血小板组织因子活性和膜胆固醇增加，而瑞舒伐他汀可使其正常化，但阿托伐他汀则不行。
Atherosclerosis. 2017 Feb;257:164-171. doi: 10.1016/j.atherosclerosis.2016.12.019. Epub 2016 Dec 16.
7
Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).前蛋白转化酶枯草溶菌素 9（PCSK9）可以介导低密度脂蛋白受体相关蛋白 1（LRP-1）的降解。
PLoS One. 2013 May 13;8(5):e64145. doi: 10.1371/journal.pone.0064145. Print 2013.
8
The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity.登革病毒感染早期胆固醇水平的升高与 LDL 颗粒摄取和 HMG-CoA 还原酶活性的增加相关。
Virology. 2013 Aug 1;442(2):132-47. doi: 10.1016/j.virol.2013.04.003. Epub 2013 May 2.
9
Increased expression of LDL receptor-related protein 1 during human cytomegalovirus infection reduces virion cholesterol and infectivity.在人类巨细胞病毒感染过程中 LDL 受体相关蛋白 1 的表达增加会降低病毒体胆固醇和感染力。
Cell Host Microbe. 2012 Jul 19;12(1):86-96. doi: 10.1016/j.chom.2012.05.012.
10
Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2.富含胆固醇的膜微区在严重急性呼吸综合征冠状病毒S蛋白与细胞受体血管紧张素转换酶2相互作用中的重要性。
Virology. 2008 Nov 25;381(2):215-21. doi: 10.1016/j.virol.2008.08.026. Epub 2008 Sep 23.
Zotero 插件